Patent intelligence · US
US 11559574
Whole-cell cancer vaccines and methods for selection thereof
Whole-cell cancer vaccines and methods for selection thereof
Patent details — US 11559574
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 24, 2023
- Expiration
- Jan 19, 2043
- Applicant
- BriaCell Therapeutics Corp.
- Claims
- 81
- CPC classes
- A61K, A61K2039/5152, A61K2039/5156, A61K2039/55522
Quick answer
US 11559574 (Whole-cell cancer vaccines and methods for selection thereof) is held by BriaCell Therapeutics Corp.. Status: granted. Granted Jan 24, 2023. Expires Jan 19, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BriaCell Therapeutics Corp.
- Grant date
- Expiration
- Claims
- 81
- CPC classes
- A61K, A61K2039/5152, A61K2039/5156, A61K2039/55522, A61K39/0011, A61K39/00112
Frequently asked questions
What is US patent 11559574?
US 11559574 (Whole-cell cancer vaccines and methods for selection thereof) is held by BriaCell Therapeutics Corp.. Status: granted. Granted Jan 24, 2023. Expires Jan 19, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11559574?
BriaCell Therapeutics Corp. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11559574 expire?
Our index shows an expiration date of Jan 19, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.